<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Jorgensen, Daniel</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Brilacidin</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">Brilacidin is a novel host defense protein being studied for the treatment of community-acquired skin and soft tissue infections. A phase 2b trial shows that a single-dose injection of brilacidin is as effective as a 7-day dose of daptomycin in treating acute bacterial skin and skin structure infections associated with Staphylococcus aureus.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>